64607-50-7

Upstream product

• 13414-95-4 4-keto-4,5,6,7-tetrahydrothianaphthene 
• 77287-34-4 formamide 
• 19995-19-8 4,5,6,7-tetrahydro-4-oxobenzo[b]thiophene oxime 
• 4653-11-6 2-thiophenebutyric acid 
• 4653-08-1 4-oxo-4-thiophen-2-yl-butyric acid 

Downstream Products

• 58095-31-1 4,5,6,7-Tetrahydro-7-oxobenzothien-4-ylharnstoff 
• 58094-06-7 N-formyl-4,5,6,7-tetrahydrobenzo[b]thiophen-4-amine 

Relevant academic research and scientific papers

New structures able to prevent the inhibition by hydroxyl radicals of glutamate transport in cultured astrocytes

4,5,6,7-Tetrahydro-benzothiophen-7-ylamines, 4,5,6,7-tetrahydro- benzothiophen-4-ylamines, and 5,6-dihydro-4H-thieno[2,3-b] thiopyran-4- ylamines were designed, synthesized, and tested as OH radical scavengers. Most of them displayed chemical scavenging properties better than or in the same range as salicylic acid. Moreover, some compounds were able to protect in vitro the astroglial glutamate transporters against inhibitory action of radicals promoted by xanthine/xanthine oxidase. Thus, such compounds might be useful for lowering the large amounts of excitotoxic glutamate liberated during acute CNS diseases: they might protect the glutamate reuptake in astrocytes from the inhibitory action due to radicals co-liberated with glutamate.

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

CXCR2 ANTAGONIST

A compound as a CXCR2 antagonist and an application thereof in preparing a drug as a CXCR2 antagonist. In particular, the present invention relates to a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof.

SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS

Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.

Substituted aryl 1,4-pyrazine derivatives

Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.

Regioselective synthesis of several heterocyclic fused azepines using diisobutylaluminum hydride

5,6,7,8-Tetrahydrothieno[3,2-b]azepine,5,6,7,8-tetrahydro-1H-furo[3,2-b] azepine, and 1,4,5,6,7,8-hexahydropyrrolo[3,2-b]azepine were synthesized by the ring expansion reaction of heterocyclic fused cyclohexanone oximes with diisobutylaluminum hydride (DIBAH). The mechanism of the reaction was different from that of Beckmann rearrangement.

Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate

This disclosure describes a novel method for improving feed efficiency and accelerating the growth rate of veterinary homothermic animals by administering to said animals a growth-promoting amount of a cycloalkano[b]thien-4-ylurea or thiourea.